Agilent Technologies, Inc.

Articles by Agilent Technologies, Inc.

In the last few years, the issuance of the ISO 10993-18:2020 medical device guidance and several high-profile publications and round-robin studies have resulted in the FDA increasing scrutiny of E&L analyses for both drugs and devices. Join our panel of industry experts to discuss these changes and to learn the direction E&L may take into the future.

Tuesday, September 28, 2021 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST In the last few years, the issuance of the ISO 10993-18:2020 medical device guidance and several high-profile publications and round-robin studies have resulted in the FDA increasing scrutiny of E&L analyses for both drugs and devices. Join our panel of industry experts to discuss these changes and to learn the direction E&L may take into the future.

Potency testing in cannabis, hemp, and cannabinoid products is required in every region where the use and production of these products is permitted by law. Although ostensibly a simple HPLC testing method, it can be fraught with potential pitfalls. These include poor extraction efficiency, poor methodology, and outcome bias from lab to lab. In this episode, we will examine these issues and discuss the utility of mass spectrometry as an alternative to address the shortcomings of HPLC.